25 XP   0   0   10

Luye Pharma Group Ltd
Buy, Hold or Sell?

Let's analyse Luye together

PenkeI guess you are interested in Luye Pharma Group Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Luye Pharma Group Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Luye Pharma Group Ltd

I send you an email if I find something interesting about Luye Pharma Group Ltd.

Quick analysis of Luye (30 sec.)










What can you expect buying and holding a share of Luye? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.00
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
HK$2.92
Expected worth in 1 year
HK$4.86
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
HK$1.94
Return On Investment
71.8%

For what price can you sell your share?

Current Price per Share
HK$2.70
Expected price per share
HK$2.34 - HK$3.42
How sure are you?
50%

1. Valuation of Luye (5 min.)




Live pricePrice per Share (EOD)

HK$2.70

Intrinsic Value Per Share

HK$-1.48 - HK$7.64

Total Value Per Share

HK$1.44 - HK$10.56

2. Growth of Luye (5 min.)




Is Luye growing?

Current yearPrevious yearGrowGrow %
How rich?$1.4b$1.1b$232.7m16.6%

How much money is Luye making?

Current yearPrevious yearGrowGrow %
Making money$83.3m-$18.5m$101.9m122.2%
Net Profit Margin10.1%-2.6%--

How much money comes from the company's main activities?

3. Financial Health of Luye (5 min.)




What can you expect buying and holding a share of Luye? (5 min.)

Welcome investor! Luye's management wants to use your money to grow the business. In return you get a share of Luye.

What can you expect buying and holding a share of Luye?

First you should know what it really means to hold a share of Luye. And how you can make/lose money.

Speculation

The Price per Share of Luye is HK$2.7. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Luye.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Luye, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$2.92. Based on the TTM, the Book Value Change Per Share is HK$0.48 per quarter. Based on the YOY, the Book Value Change Per Share is HK$0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Luye.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps0.020.8%0.020.8%0.00-0.2%0.031.1%0.031.0%
Usd Book Value Change Per Share0.062.3%0.062.3%0.010.5%0.020.9%0.031.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.2%0.010.2%
Usd Total Gains Per Share0.062.3%0.062.3%0.010.5%0.031.1%0.041.4%
Usd Price Per Share0.47-0.47-0.45-0.56-0.65-
Price to Earnings Ratio21.08-21.08--92.28--5.00-10.97-
Price-to-Total Gains Ratio7.55-7.55-31.87-10.70-17.15-
Price to Book Ratio1.25-1.25-1.46-1.77-2.62-
Price-to-Total Gains Ratio7.55-7.55-31.87-10.70-17.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.34479
Number of shares2900
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.060.02
Usd Total Gains Per Share0.060.03
Gains per Quarter (2900 shares)179.4287.64
Gains per Year (2900 shares)717.70350.55
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1071870872279341
2014351426143558692
30215321442158371043
402871286228611161394
503588358035813951745
604306429843016742096
705024501650119532447
805742573457322322798
906459645264425113149
1007177717071627893500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%18.01.01.090.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%19.01.00.095.0%
Dividend per Share0.00.01.00.0%1.00.02.033.3%3.00.02.060.0%8.00.02.080.0%14.00.06.070.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%19.01.00.095.0%

Fundamentals of Luye

About Luye Pharma Group Ltd

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-16 05:36:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Luye Pharma Group Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Luye earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Luye to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 10.1% means that $0.10 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Luye Pharma Group Ltd:

  • The MRQ is 10.1%. The company is making a huge profit. +2
  • The TTM is 10.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ10.1%TTM10.1%0.0%
TTM10.1%YOY-2.6%+12.7%
TTM10.1%5Y13.7%-3.6%
5Y13.7%10Y18.6%-4.9%
1.1.2. Return on Assets

Shows how efficient Luye is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Luye to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.5% Return on Assets means that Luye generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Luye Pharma Group Ltd:

  • The MRQ is 2.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.5%TTM2.5%0.0%
TTM2.5%YOY-0.6%+3.1%
TTM2.5%5Y4.1%-1.6%
5Y4.1%10Y6.9%-2.8%
1.1.3. Return on Equity

Shows how efficient Luye is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Luye to the Drug Manufacturers - Specialty & Generic industry mean.
  • 5.9% Return on Equity means Luye generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Luye Pharma Group Ltd:

  • The MRQ is 5.9%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.9%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.9%TTM5.9%0.0%
TTM5.9%YOY-1.6%+7.5%
TTM5.9%5Y9.3%-3.4%
5Y9.3%10Y11.8%-2.5%

1.2. Operating Efficiency of Luye Pharma Group Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Luye is operating .

  • Measures how much profit Luye makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Luye to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 13.2% means the company generated $0.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Luye Pharma Group Ltd:

  • The MRQ is 13.2%. The company is operating less efficient.
  • The TTM is 13.2%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ13.2%TTM13.2%0.0%
TTM13.2%YOY7.0%+6.2%
TTM13.2%5Y20.1%-6.9%
5Y20.1%10Y23.2%-3.1%
1.2.2. Operating Ratio

Measures how efficient Luye is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.15 means that the operating costs are $1.15 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Luye Pharma Group Ltd:

  • The MRQ is 1.148. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.148. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.148TTM1.1480.000
TTM1.148YOY1.292-0.144
TTM1.1485Y0.983+0.165
5Y0.98310Y0.860+0.123

1.3. Liquidity of Luye Pharma Group Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Luye is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.14 means the company has $1.14 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Luye Pharma Group Ltd:

  • The MRQ is 1.137. The company is just able to pay all its short-term debts.
  • The TTM is 1.137. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.137TTM1.1370.000
TTM1.137YOY1.418-0.281
TTM1.1375Y1.336-0.199
5Y1.33610Y2.071-0.736
1.3.2. Quick Ratio

Measures if Luye is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Luye to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.07 means the company can pay off $1.07 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Luye Pharma Group Ltd:

  • The MRQ is 1.075. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.075. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.075TTM1.0750.000
TTM1.075YOY1.377-0.303
TTM1.0755Y1.325-0.250
5Y1.32510Y2.134-0.809

1.4. Solvency of Luye Pharma Group Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Luye assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Luye to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.58 means that Luye assets are financed with 58.0% credit (debt) and the remaining percentage (100% - 58.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Luye Pharma Group Ltd:

  • The MRQ is 0.580. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.580. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.580TTM0.5800.000
TTM0.580YOY0.624-0.044
TTM0.5805Y0.575+0.006
5Y0.57510Y0.432+0.143
1.4.2. Debt to Equity Ratio

Measures if Luye is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Luye to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 138.3% means that company has $1.38 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Luye Pharma Group Ltd:

  • The MRQ is 1.383. The company is able to pay all its debts with equity. +1
  • The TTM is 1.383. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.383TTM1.3830.000
TTM1.383YOY1.660-0.277
TTM1.3835Y1.397-0.014
5Y1.39710Y0.926+0.472

2. Market Valuation of Luye Pharma Group Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Luye generates.

  • Above 15 is considered overpriced but always compare Luye to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 21.08 means the investor is paying $21.08 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Luye Pharma Group Ltd:

  • The EOD is 15.552. Based on the earnings, the company is fair priced.
  • The MRQ is 21.082. Based on the earnings, the company is fair priced.
  • The TTM is 21.082. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD15.552MRQ21.082-5.530
MRQ21.082TTM21.0820.000
TTM21.082YOY-92.281+113.363
TTM21.0825Y-4.996+26.078
5Y-4.99610Y10.968-15.964
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Luye Pharma Group Ltd:

  • The EOD is 19.190. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 26.014. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 26.014. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD19.190MRQ26.014-6.823
MRQ26.014TTM26.0140.000
TTM26.014YOY-9.124+35.138
TTM26.0145Y-7.184+33.198
5Y-7.18410Y140.408-147.593
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Luye is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Luye Pharma Group Ltd:

  • The EOD is 0.924. Based on the equity, the company is cheap. +2
  • The MRQ is 1.253. Based on the equity, the company is underpriced. +1
  • The TTM is 1.253. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.924MRQ1.253-0.329
MRQ1.253TTM1.2530.000
TTM1.253YOY1.461-0.208
TTM1.2535Y1.766-0.513
5Y1.76610Y2.615-0.849
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Luye Pharma Group Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4840.4840%0.112+334%0.188+157%0.247+96%
Book Value Per Share--2.9212.9210%2.437+20%2.530+15%2.017+45%
Current Ratio--1.1371.1370%1.418-20%1.336-15%2.071-45%
Debt To Asset Ratio--0.5800.5800%0.624-7%0.575+1%0.432+34%
Debt To Equity Ratio--1.3831.3830%1.660-17%1.397-1%0.926+49%
Dividend Per Share----0%-0%0.048-100%0.043-100%
Eps--0.1740.1740%-0.039+122%0.227-23%0.215-19%
Free Cash Flow Per Share--0.1410.1410%-0.390+377%-0.245+274%-0.094+167%
Free Cash Flow To Equity Per Share--0.1560.1560%0.149+5%0.111+41%0.209-25%
Gross Profit Margin--1.0001.0000%1.0000%-0.007+101%-0.599+160%
Intrinsic Value_10Y_max--7.642--------
Intrinsic Value_10Y_min---1.484--------
Intrinsic Value_1Y_max--0.092--------
Intrinsic Value_1Y_min---0.223--------
Intrinsic Value_3Y_max--0.789--------
Intrinsic Value_3Y_min---0.610--------
Intrinsic Value_5Y_max--2.106--------
Intrinsic Value_5Y_min---0.928--------
Market Cap10156508697.600-36%13767711790.08013767711790.0800%13391544801.280+3%16641627584.512-17%19169469749.248-28%
Net Profit Margin--0.1010.1010%-0.026+126%0.137-26%0.186-46%
Operating Margin--0.1320.1320%0.070+89%0.201-34%0.232-43%
Operating Ratio--1.1481.1480%1.292-11%0.983+17%0.860+34%
Pb Ratio0.924-36%1.2531.2530%1.461-14%1.766-29%2.615-52%
Pe Ratio15.552-36%21.08221.0820%-92.281+538%-4.996+124%10.968+92%
Price Per Share2.700-36%3.6603.6600%3.560+3%4.424-17%5.096-28%
Price To Free Cash Flow Ratio19.190-36%26.01426.0140%-9.124+135%-7.184+128%140.408-81%
Price To Total Gains Ratio5.573-36%7.5547.5540%31.873-76%10.695-29%17.150-56%
Quick Ratio--1.0751.0750%1.377-22%1.325-19%2.134-50%
Return On Assets--0.0250.0250%-0.006+124%0.041-39%0.069-64%
Return On Equity--0.0590.0590%-0.016+127%0.093-36%0.118-50%
Total Gains Per Share--0.4840.4840%0.112+334%0.237+105%0.289+68%
Usd Book Value--1403166977.9991403166977.9990%1170431185.007+20%1215337915.959+15%968841344.511+45%
Usd Book Value Change Per Share--0.0620.0620%0.014+334%0.024+157%0.031+96%
Usd Book Value Per Share--0.3730.3730%0.311+20%0.323+15%0.258+45%
Usd Dividend Per Share----0%-0%0.006-100%0.005-100%
Usd Eps--0.0220.0220%-0.005+122%0.029-23%0.027-19%
Usd Free Cash Flow--67585216.39367585216.3930%-187424022.603+377%-117829907.676+274%-45181905.154+167%
Usd Free Cash Flow Per Share--0.0180.0180%-0.050+377%-0.031+274%-0.012+167%
Usd Free Cash Flow To Equity Per Share--0.0200.0200%0.019+5%0.014+41%0.027-25%
Usd Market Cap1296986160.684-36%1758136795.5931758136795.5930%1710100271.123+3%2125135842.542-17%2447941286.979-28%
Usd Price Per Share0.345-36%0.4670.4670%0.455+3%0.565-17%0.651-28%
Usd Profit--83397115.44183397115.4410%-18531374.700+122%108904120.310-23%103312937.938-19%
Usd Revenue--824813297.402824813297.4020%717061555.244+15%779150154.542+6%595929474.410+38%
Usd Total Gains Per Share--0.0620.0620%0.014+334%0.030+105%0.037+68%
 EOD+4 -4MRQTTM+0 -0YOY+27 -65Y+17 -1910Y+15 -21

3.2. Fundamental Score

Let's check the fundamental score of Luye Pharma Group Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.552
Price to Book Ratio (EOD)Between0-10.924
Net Profit Margin (MRQ)Greater than00.101
Operating Margin (MRQ)Greater than00.132
Quick Ratio (MRQ)Greater than11.075
Current Ratio (MRQ)Greater than11.137
Debt to Asset Ratio (MRQ)Less than10.580
Debt to Equity Ratio (MRQ)Less than11.383
Return on Equity (MRQ)Greater than0.150.059
Return on Assets (MRQ)Greater than0.050.025
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Luye Pharma Group Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.105
Ma 20Greater thanMa 502.731
Ma 50Greater thanMa 1002.791
Ma 100Greater thanMa 2003.071
OpenGreater thanClose2.650
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets24,249,625
Total Liabilities14,073,671
Total Stockholder Equity10,175,954
 As reported
Total Liabilities 14,073,671
Total Stockholder Equity+ 10,175,954
Total Assets = 24,249,625

Assets

Total Assets24,249,625
Total Current Assets10,785,813
Long-term Assets13,463,812
Total Current Assets
Cash And Cash Equivalents 2,323,740
Short-term Investments 3,220,524
Net Receivables 1,431,843
Inventory 772,939
Other Current Assets 1,651,831
Total Current Assets  (as reported)10,785,813
Total Current Assets  (calculated)9,400,877
+/- 1,384,936
Long-term Assets
Property Plant Equipment 4,909,126
Goodwill 1,003,371
Intangible Assets 5,984,684
Other Assets 772,376
Long-term Assets  (as reported)13,463,812
Long-term Assets  (calculated)12,669,557
+/- 794,255

Liabilities & Shareholders' Equity

Total Current Liabilities9,487,203
Long-term Liabilities3,720,700
Total Stockholder Equity10,175,954
Total Current Liabilities
Short-term Debt 4,864,900
Short Long Term Debt 6,824,534
Accounts payable 559,944
Other Current Liabilities 1,999,766
Total Current Liabilities  (as reported)9,487,203
Total Current Liabilities  (calculated)14,249,144
+/- 4,761,941
Long-term Liabilities
Long term Debt Total 2,264,731
Other Liabilities 1,455,969
Long-term Liabilities  (as reported)3,720,700
Long-term Liabilities  (calculated)3,720,700
+/-0
Total Stockholder Equity
Retained Earnings 6,909,994
Capital Surplus 3,076,828
Total Stockholder Equity (as reported)10,175,954
Total Stockholder Equity (calculated)9,986,822
+/- 189,132
Other
Capital Stock456,953
Cash And Equivalents2,323,740
Cash and Short Term Investments 5,544,264
Common Stock Shares Outstanding 3,529,671
Liabilities and Stockholders Equity 24,249,625
Net Debt 6,742,288
Net Invested Capital 19,241,982
Net Tangible Assets 3,187,899
Net Working Capital 1,298,610
Property Plant and Equipment Gross 6,893,542



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
273,545
373,048
392,994
839,183
1,133,310
1,066,720
1,523,975
1,822,167
2,454,387
2,677,627
3,387,463
6,130,756
7,052,922
9,205,847
10,760,400
17,538,810
19,313,938
20,630,566
22,582,061
24,249,625
24,249,62522,582,06120,630,56619,313,93817,538,81010,760,4009,205,8477,052,9226,130,7563,387,4632,677,6272,454,3871,822,1671,523,9751,066,7201,133,310839,183392,994373,048273,545
   > Total Current Assets 
162,210
262,472
253,778
335,382
465,276
446,266
735,379
895,360
930,173
0
1,652,370
3,525,955
5,071,444
5,282,457
6,295,932
8,675,308
9,359,843
9,970,441
10,396,664
10,785,813
10,785,81310,396,6649,970,4419,359,8438,675,3086,295,9325,282,4575,071,4443,525,9551,652,3700930,173895,360735,379446,266465,276335,382253,778262,472162,210
       Cash And Cash Equivalents 
54,141
132,671
70,399
95,577
142,886
118,469
275,311
400,135
251,501
364,031
333,150
331,863
843,674
397,775
1,265,872
1,672,865
2,325,446
3,865,385
2,438,252
2,323,740
2,323,7402,438,2523,865,3852,325,4461,672,8651,265,872397,775843,674331,863333,150364,031251,501400,135275,311118,469142,88695,57770,399132,67154,141
       Short-term Investments 
10,300
127,778
47,000
16,061
20,480
0
45,126
54,500
79,009
2,464
10,000
1,845,392
2,362,709
2,349,622
2,575,499
3,189,707
2,862,639
1,540,907
3,072,057
3,220,524
3,220,5243,072,0571,540,9072,862,6393,189,7072,575,4992,349,6222,362,7091,845,39210,0002,46479,00954,50045,126020,48016,06147,000127,77810,300
       Net Receivables 
75,344
96,782
145,509
184,696
244,560
238,605
307,842
341,867
477,509
542,240
876,920
952,445
620,430
1,546,826
1,489,930
1,633,060
1,825,462
1,806,611
1,514,781
1,431,843
1,431,8431,514,7811,806,6111,825,4621,633,0601,489,9301,546,826620,430952,445876,920542,240477,509341,867307,842238,605244,560184,696145,50996,78275,344
       Inventory 
16,343
28,623
29,110
33,649
42,250
56,028
57,630
73,279
105,382
142,686
234,733
251,198
285,609
452,670
420,356
585,609
614,622
612,303
746,344
772,939
772,939746,344612,303614,622585,609420,356452,670285,609251,198234,733142,686105,38273,27957,63056,02842,25033,64929,11028,62316,343
       Other Current Assets 
6,082
4,396
8,760
5,399
15,100
33,164
49,470
25,579
16,772
37,147
20,082
17,842
270,404
1,082,841
1,615,106
2,932,148
3,011,008
2,151,538
1,706,509
1,651,831
1,651,8311,706,5092,151,5383,011,0082,932,1481,615,1061,082,841270,40417,84220,08237,14716,77225,57949,47033,16415,1005,3998,7604,3966,082
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
3,923,390
4,464,468
8,863,502
9,954,095
10,660,125
12,185,397
13,463,812
13,463,81212,185,39710,660,1259,954,0958,863,5024,464,4683,923,3900000000000000
       Property Plant Equipment 
100,338
95,201
122,029
108,898
149,306
152,434
205,001
319,397
669,728
777,769
925,824
1,092,151
1,245,024
1,701,739
2,009,970
2,837,140
4,213,436
4,339,336
4,594,470
4,909,126
4,909,1264,594,4704,339,3364,213,4362,837,1402,009,9701,701,7391,245,0241,092,151925,824777,769669,728319,397205,001152,434149,306108,898122,02995,201100,338
       Goodwill 
0
0
5,880
44,398
168,726
165,936
188,212
188,212
359,356
347,356
347,356
347,356
347,356
995,921
1,036,902
1,040,879
1,038,068
1,056,583
985,413
1,003,371
1,003,371985,4131,056,5831,038,0681,040,8791,036,902995,921347,356347,356347,356347,356359,356188,212188,212165,936168,72644,3985,88000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
9,654
7,727
7,692
8,486
40,808
83,566
0
0
0
0
000083,56640,8088,4867,6927,7279,6540000000000
       Intangible Assets 
10,293
9,353
8,702
47,955
222,098
200,396
367,086
340,500
406,462
521,119
136,301
145,888
126,216
855,676
828,702
4,445,063
4,486,866
4,770,004
5,441,833
5,984,684
5,984,6845,441,8334,770,0044,486,8664,445,063828,702855,676126,216145,888136,301521,119406,462340,500367,086200,396222,09847,9558,7029,35310,293
       Other Assets 
204
5,522
4,805
293,456
8,344
9,728
23,641
71,199
82,606
283,082
315,958
1,011,679
255,190
473,782
682,945
623,648
1,333,768
1,751,817
2,334,474
772,376
772,3762,334,4741,751,8171,333,768623,648682,945473,782255,1901,011,679315,958283,08282,60671,19923,6419,7288,344293,4564,8055,522204
> Total Liabilities 
170,377
89,665
43,488
111,068
356,762
244,856
429,240
573,984
1,050,000
1,093,820
1,489,768
1,093,196
1,253,391
2,643,846
3,864,484
9,604,781
9,942,096
12,531,551
14,093,938
14,073,671
14,073,67114,093,93812,531,5519,942,0969,604,7813,864,4842,643,8461,253,3911,093,1961,489,7681,093,8201,050,000573,984429,240244,856356,762111,06843,48889,665170,377
   > Total Current Liabilities 
127,771
78,086
41,009
107,605
214,155
138,756
323,848
458,999
890,987
884,200
1,302,983
888,236
1,045,427
2,374,776
3,654,797
8,202,930
5,546,487
7,234,094
7,330,193
9,487,203
9,487,2037,330,1937,234,0945,546,4878,202,9303,654,7972,374,7761,045,427888,2361,302,983884,200890,987458,999323,848138,756214,155107,60541,00978,086127,771
       Short-term Debt 
0
0
0
0
0
0
45,126
54,500
79,009
0
10,000
1,845,392
2,362,709
2,349,622
2,575,499
3,189,707
2,862,639
5,629,842
4,739,854
4,864,900
4,864,9004,739,8545,629,8422,862,6393,189,7072,575,4992,349,6222,362,7091,845,39210,000079,00954,50045,126000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
745,308
305,537
502,715
1,623,597
2,860,979
5,290,397
3,926,938
5,629,842
5,240,471
6,824,534
6,824,5345,240,4715,629,8423,926,9385,290,3972,860,9791,623,597502,715305,537745,3080000000000
       Accounts payable 
12,204
9,512
9,755
9,117
8,253
11,735
13,450
20,296
34,331
54,403
69,369
59,044
83,219
116,142
104,599
279,750
298,477
485,262
570,890
559,944
559,944570,890485,262298,477279,750104,599116,14283,21959,04469,36954,40334,33120,29613,45011,7358,2539,1179,7559,51212,204
       Other Current Liabilities 
27,557
19,574
20,514
69,555
68,624
61,172
139,711
174,563
402,841
384,934
497,693
524,293
272,987
438,228
438,829
2,253,878
968,184
895,510
1,065,676
1,999,766
1,999,7661,065,676895,510968,1842,253,878438,829438,228272,987524,293497,693384,934402,841174,563139,71161,17268,62469,55520,51419,57427,557
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
269,070
209,687
1,401,851
4,395,609
5,297,457
6,137,965
3,720,700
3,720,7006,137,9655,297,4574,395,6091,401,851209,687269,0700000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
493
372
232
847,596
4,510,293
4,338,645
4,227,577
2,264,731
2,264,7314,227,5774,338,6454,510,293847,596232372493000000000000
       Other Liabilities 
0
0
2,479
1,817
1,027
0
5,250
32,129
63,030
66,577
78,684
106,605
207,471
268,698
209,455
554,255
273,316
958,812
1,910,388
1,455,969
1,455,9691,910,388958,812273,316554,255209,455268,698207,471106,60578,68466,57763,03032,1295,25001,0271,8172,47900
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
292
0
0
112,214
134,859
166,794
394,818
1,005,396
1,361,999
0
01,361,9991,005,396394,818166,794134,859112,214002920000000000
> Total Stockholder Equity
96,291
272,090
345,032
727,557
775,926
821,286
987,298
1,126,445
1,277,182
1,460,420
1,769,042
4,907,598
5,663,961
6,428,543
6,768,403
7,808,413
8,831,625
7,891,231
8,488,123
10,175,954
10,175,9548,488,1237,891,2318,831,6257,808,4136,768,4036,428,5435,663,9614,907,5981,769,0421,460,4201,277,1821,126,445987,298821,286775,926727,557345,032272,09096,291
   Common Stock
0
67,579
67,579
80,408
81,180
81,180
81,180
81,180
81,180
81,180
81,180
427,269
427,269
427,269
427,269
421,337
420,565
417,991
455,835
456,953
456,953455,835417,991420,565421,337427,269427,269427,269427,26981,18081,18081,18081,18081,18081,18081,18080,40867,57967,5790
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income 000-1,082,905-888,709-735,072-592,788-348,191-290,230-232,8410-169,637-145,259-123,784-111,22100000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
2,936,817
2,936,817
2,936,817
2,764,669
2,671,071
1,042,005
1,715,981
3,076,828
3,076,8281,715,9811,042,0052,671,0712,764,6692,936,8172,936,8172,936,817000000000000
   Treasury Stock0-279,558-279,558-279,558-305,626-459,284000000000-2,0110000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
36,500
38,945
-2,644
20,804
55,609
92,802
423,267
501,516
534,036
6,921,731
6,921,731534,036501,516423,26792,80255,60920,804-2,64438,94536,5000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue5,981,656
Cost of Revenue-1,841,140
Gross Profit4,140,5164,140,516
 
Operating Income (+$)
Gross Profit4,140,516
Operating Expense-5,027,778
Operating Income1,140,686-887,262
 
Operating Expense (+$)
Research Development857,337
Selling General Administrative2,402,561
Selling And Marketing Expenses0
Operating Expense5,027,7783,259,898
 
Net Interest Income (+$)
Interest Income470,924
Interest Expense-238,224
Other Finance Cost-615,782
Net Interest Income-383,082
 
Pretax Income (+$)
Operating Income1,140,686
Net Interest Income-383,082
Other Non-Operating Income Expenses0
Income Before Tax (EBT)669,7621,140,686
EBIT - interestExpense = 550,914
691,273
843,031
Interest Expense238,224
Earnings Before Interest and Taxes (EBIT)789,138907,986
Earnings Before Interest and Taxes (EBITDA)1,812,830
 
After tax Income (+$)
Income Before Tax669,762
Tax Provision-86,466
Net Income From Continuing Ops583,296583,296
Net Income604,807
Net Income Applicable To Common Shares604,807
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses948,817
Total Other Income/Expenses Net0383,082
 

Technical Analysis of Luye
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Luye. The general trend of Luye is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Luye's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Luye Pharma Group Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.1 < 3.2 < 3.42.

The bearish price targets are: 2.36 > 2.35 > 2.34.

Tweet this
Luye Pharma Group Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Luye Pharma Group Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Luye Pharma Group Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Luye Pharma Group Ltd. The current macd is -0.05442436.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Luye price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Luye. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Luye price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Luye Pharma Group Ltd Daily Moving Average Convergence/Divergence (MACD) ChartLuye Pharma Group Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Luye Pharma Group Ltd. The current adx is 17.52.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Luye shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Luye Pharma Group Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Luye Pharma Group Ltd. The current sar is 2.558688.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Luye Pharma Group Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Luye Pharma Group Ltd. The current rsi is 46.11. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Luye Pharma Group Ltd Daily Relative Strength Index (RSI) ChartLuye Pharma Group Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Luye Pharma Group Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Luye price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Luye Pharma Group Ltd Daily Stochastic Oscillator ChartLuye Pharma Group Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Luye Pharma Group Ltd. The current cci is -33.18649046.

Luye Pharma Group Ltd Daily Commodity Channel Index (CCI) ChartLuye Pharma Group Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Luye Pharma Group Ltd. The current cmo is -4.22350667.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Luye Pharma Group Ltd Daily Chande Momentum Oscillator (CMO) ChartLuye Pharma Group Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Luye Pharma Group Ltd. The current willr is -48.27586207.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Luye is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Luye Pharma Group Ltd Daily Williams %R ChartLuye Pharma Group Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Luye Pharma Group Ltd.

Luye Pharma Group Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Luye Pharma Group Ltd. The current atr is 0.10461547.

Luye Pharma Group Ltd Daily Average True Range (ATR) ChartLuye Pharma Group Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Luye Pharma Group Ltd. The current obv is 270,079,424.

Luye Pharma Group Ltd Daily On-Balance Volume (OBV) ChartLuye Pharma Group Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Luye Pharma Group Ltd. The current mfi is 53.95.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Luye Pharma Group Ltd Daily Money Flow Index (MFI) ChartLuye Pharma Group Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Luye Pharma Group Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Luye Pharma Group Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Luye Pharma Group Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.105
Ma 20Greater thanMa 502.731
Ma 50Greater thanMa 1002.791
Ma 100Greater thanMa 2003.071
OpenGreater thanClose2.650
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Luye with someone you think should read this too:
  • Are you bullish or bearish on Luye? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Luye? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Luye Pharma Group Ltd

I send you an email if I find something interesting about Luye Pharma Group Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Luye Pharma Group Ltd.

Receive notifications about Luye Pharma Group Ltd in your mailbox!